Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 204-212

  Kamali, Farhad ^a   Khan, Tayyaba Irfan ^b   King, Barry P ^b   Frearson, Richard ^b   Kesteven, Patrick ^b   Wood, Peter ^b   Daly, Ann K ^b   Wynne, Hilary ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; TRIACYLGLYCEROL; VITAMIN K GROUP; WARFARIN;

ADULT; ARTICLE; BODY SIZE; BODY SURFACE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; REGRESSION ANALYSIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BODY CONSTITUTION; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; WARFARIN;

EID: 1542346414     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.10.001     Document Type: Article

References (25)

1. Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57. [Published erratum appears in Arch Intern Med 1994;154:2254.]
2. Gladman J.R.F., Dolan G. Effect of age upon the induction and maintenance of anticoagulation with warfarin. Postgrad Med J. 71:1995;153-155.
3. Loh P.C., Morgan K., Wynne H. Anticoagulation of older patients a need to modify current practice. [letter] Age Ageing. 29:2000;551.
4. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allele variant of CYP2C9. Pharmacogenetics. 4:1994;39-42.
5. Haining R.L., Hunter A.P., Veronese M.E., Trager W.F., Rettie A.E. Allelic variants of human cytochrome P-450 2C9 baculovirus-mediated expression purification, structural characterization, substance stereoselectivity and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys. 333:1996;447-458.
6. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349.
7. Aithal G.P., Day C.P., Kesteven P.J.L., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719.
8. Minors J.O., Birkett D.J. Cytochrome P4502C9 an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 45:1998;525-538.
9. Mattock M, Shearer MJ, Rahm S, Redmond S, El-Gohari R, Barkhan P. The plasma transport of vitamin K1 (phylloquinone) in hyperlipoproteinaemia [abstract]. Clin Sci 1983;64:63
10. Wynne H., Cope L., Kelly P., Edwards C., Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol. 40:1995;203-207.
11. Routledge P.A., Chapman P.H., Davies D.M., Rawlins M.D. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol. 15:1979;319-322.
12. Naidong W., Lee J.W. Development and validation of a high performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma. J Pharm Biomed Anal. 11:1993;785-792.
13. Davidson K.W., Sadowski J.A. Determination of vitamin K compounds in plasma or serum by high performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol. 282:1997;408-421.
14. Bucolo G., David H. The quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 19:1973;476-482.
15. Daly A.K., Steen V.M., Fairbrother K.S., Idle J.R. CYP2D6 multiallelism. Methods Enzymol. 272:1996;199-210.
16. Wang S.-L., Huang J.-D., Lai M.-D., Tsai J.-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 5:1995;37-42.
17. DuBois D., DuBois E.F. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 17:1916;863-871.
18. Rowland M., Tozer T.N. Multiple dose regimens. Rowland M., Tozer T.N. Clinical pharmacokinetics, concepts and implications. 3rd ed. 1995;83-105 Williams & Wilkins, Baltimore (MD).
19. Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 72:2002;702-710.
20. Kamali F., Edwards C., Wood P., Wynne H., Kesteven P. Temporal variations in plasma clotting factor activity in man. Am J Hematol. 68:2001;159-163.
21. Loebstein R.L., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther. 70:2001;159-164.
22. Miners J.O., Birkett D.J. Cytochrome P4502C9 an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 45:1998;525-538.
23. Scordo M.G., Aklillu E., Yasar U., Dahl M.L., Spina E., Ingleman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and Black African population. Br J Clin Pharmacol. 52:2001;447-450.
24. Yassar U., Eliasson E., Dahl M.L., Johansson I., Ingleman-Sundberg M., Sjoqvist F. Validation of methods for CYP2C9 genotyping frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 254:1999;628-631.
25. Wynne H., Kamali F., Edwards C., Long A., Kelly P. Effect of age upon warfarin dosage requirements a longitudinal study. Age Ageing. 25:1996;429-431.